Japan Diagnostic Imaging Market Trends

The oncology segment is expected to have significant growth in the nation, owing to the rising cancer cases, and increasing technological innovations in the image diagnostics segment.

According to the Globocan 2020 report, an estimate of around 1.03 million people in Japan were affected by cancer. The large number of population affected by cancer in the nation, increases the demand for the proper diagnostics of the disease for the healthcare providers to provide the proper surgical or non-surgical treatment. Thus, the rise in the demand for the clinical diagnostic imaging is expected to boost the growth of the diagnostic imaging market in Japan over the forecast period.

Diagnostic imaging plays a vital role in interventional oncology (with rising opportunities to diagnose and treat in a targeted and minimally or non-invasive manner) as well as in chemo and radiation therapy. Tools, such as CT, are the highly beneficial and preferred method of imaging for many conditions, including trauma patients. Comparatively, PET is mostly preferred as compared to SPECT, and there are hybrid medical devices also available such as PET/CT or PET/MRI.

Several key market players focusing on the diagnostic imaging in Japan are also aiding the growth of the market. For instance, in July 2020, Philips announced the launch of its Lumify handheld ultrasound solution in Japan. Lumify is a highly versatile solution primarily intended for use in places where quick and easy access to diagnostic ultrasound imaging is required. Such product launches are propelling the growth of the market. 

As Japan has a developed healthcare system, these technologies have been implemented into the routine and have been helping the patients and physicians as well. Hence, an increased prevalence of cancer and the implementation of new technologies are expected to help this segment dominate the market.